Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Immunization in High-Risk Melanoma
NCT00059475Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2003
- Primary completion
- May 2010
- Modality
- Modified Peptides, Peptide-based Cancer Vaccines, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of MART-1(27-35) peptide vaccine, mart-1 (27-35) (27l) peptide, melan-a analog peptide, gp100:209-217(210M) in melanoma, sponsored by National Cancer Institute. Started Apr 2003; status: completed.
02
Drugs
MART-1(27-35) peptide vaccinemart-1 (27-35) (27l) peptidemelan-a analog peptidegp100:209-217(210M)
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00059475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00059475.